BIO trade ideas
BIO: some upside potential?A price action above 340 supports a bullish trend direction.
Bullish confirmation for a break above 354.00.
The target price is set at 397.00.
The stop-loss price is set at 322 (its 50% Fibonacci retracement level).
Breaking above its 200-day might trigger further upside potential.
Remains a risky trade.
BIO: some upside?A price action above 448 supports a bullish trend direction.
The stock is testing its 200-day simple moving average. A change in sentiment towards bullish might occur.
Further bullish confirmation for a break above 478.
Profit target is at 498.
Stop-loss is at 443.
Type of a broadening top pattern is busy unfolding. The upper range is highlighted by the 200-week simple moving average.
BIO: some waterfall price action?A price action below 460 supports a bearish trend direction.
The stock is testing its 200-day simple moving average. A confirmed cross below this level will change the sentiment to a full-blown bearish sentiment.
Increase short exposure for a break below 450.
The target price is set at 420.
Stop-loss at 490.
Negate the bearish stance for a break above 460.
The waterfall price effect in stocks refers to a sharp and significant drop in the price of a stock due to a large sell-off by institutional investors or traders. The term "waterfall" is used to describe the downward movement of the stock price, which looks like a waterfall on a price chart.
BIO | Medical Device Co | Good EntryBio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Educational Materials nr.5 Net Margin is bigger than Operating Hello dear investors,
This article is about rare situation, when net margin is bigger then operating margin. Such situation need to be analyzed well to understanding potential of the company.
This happen from external or internal reasons:
1. When company can’t pay taxes and/or have tax benefits. Company will not pay taxes untill she will get net profit as tax benefit. Profit from tax benefit can be holded or payed as dividends. It have good influence on stock growning. In some countries this situation can be because of low or zero taxation.
2. Net profit can be from non-operating activity. It is income from investing activity of the company, selling assets, currency course changing and so on. Company can make her status better in a financial statement. It will seems from big difference between P/E and P/E without NRI. That is mean, that company have most income not from operating activity and is bad signal for investors.
Analysis on a BIO case.
Net margine is bigger then operating in 8 times. Company has difference between P/E and Price-to-Free-Cash-Flow in 8 times. It means, that declared income does not supported by real result. P/E equality to the P/E without NRI means, that company have income just from operating activity.
In this case reason of bigger meaning net margin from operating margin is in taxation. Company does not have cash to pay taxes, so she had tax benefits. She wrote this tax benefits in net income.
Cases, when net margin is bigger then operating are rare and need serious research and analysis to understand profitability from investing in this company.
Wish you have good investing and big profits,
Financial analist and adviser,
Valerii Selin
BIO LONG TRADEBIO has formed a bullish pinbar at the 100 EMA which has previously acted as support, so I would expect the price to bounce off this level
BIO is also a fundamentaly good company, and the coronavirus hasn't really affected it as much as the overall stock market, so if we should go long in a stock, BIO could be a potentially good trade
Because of the high volatility that we see in the market right now, our SL range should be pretty wide and i will only take the trade if price moves above the pinbar
Also my postions size will be smaller because of the volatility
Risk to reward = 1/2